416 results on '"Baldwin, Hilary"'
Search Results
152. Isotretinoin: mechanism of action and patient selection
- Author
-
Webster, Guy F., Leyden, James J., Baldwin, Hilary E., and Zaenglein, Andrea L.
- Subjects
United States. Food and Drug Administration ,Ranbaxy Laboratories Ltd. ,Isotretinoin ,Antiacne agents ,Acne ,Pharmaceutical industry ,Health ,Health care industry - Abstract
Abstract Oral isotretinoin is a highly effective treatment for appropriately selected patients with acne. This medication is the only treatment that targets all four of the identified factors underlying acne [...]
- Published
- 2015
153. Medical Hazards of the Tear Gas CS
- Author
-
HILL, A. ROSS, SILVERBERG, NANETTE B., MAYORGA, DAVID, and BALDWIN, HILARY E.
- Subjects
Tear gas -- Health aspects ,Gases, Asphyxiating and poisonous -- Health aspects - Published
- 2000
154. Keloid Management
- Author
-
Baldwin Hilary
- Published
- 2010
155. Introduction: reframing the isotretinoin discussion
- Author
-
Baldwin, Hilary E.
- Subjects
Ranbaxy Laboratories Ltd. ,Acne ,Isotretinoin ,Pharmaceutical industry ,Antiacne agents ,Health ,Health care industry - Abstract
The effective treatment of most patients with mild-to-moderate acne vulgaris is readily accomplished using evidenced-based guidelines. At a recent clinical roundtable--from which this educational supplement was derived--the faculty reviewed the [...]
- Published
- 2015
156. Lista de Colaboradores
- Author
-
Aasi, Sumaira Z, Acosta, Alvaro E, Affleck, Andrew G, Alam, Murad, Amini, Sadegh, Arndt, Kenneth A, Arpey, Christopher J, Baldwin, Hilary, Bello, Ysabel, Berman, Brian, Bernstein, Robert M, Bhatia, Ashish C, Bolotin, Diana, Book, Samuel E, Breithaupt, Andrew, Breu, Franz X, Brown, Katherine L, Butterwick, Kimberly J, Cao, Theresa, Carney, J Michael, Cartee, Todd V, Chan, Henry Hin Lee, Chan, Johnny Chun Yin, Charles, Carlos A, Chesnut, Cameron, Colver, Graham, Cook, Jonathan L, Countryman, Nicholas B, Donofrio, Lisa M, Falabella, Anna F, Fernández-Obregón, Adolfo C, Fincher, Edgar F, Fratila, Alina, Ghannam, Sahar F, Gladstone, Hayes B, Glaser, Dee Anna, Goldberg, Leonard H, Goldman, Glenn D, Goldsberry, Anne, Goodman, Greg J, Greenway, Hubert T, Hamzavi, Iltefat, Haneke, Eckart, Hanke, C William, Hanlon, Allison, Hexsel, Camile L, Hexsel, Doris, Holmes, Todd E, Hruza, George J, Hsu, Jeffrey T S, Ibrahimi, Omar A, Isenhath, Scott N, Iyengar, Vivek, Kaminer, Michael S, Khachemoune, Amor, Khunger, Niti, Kilmer, Suzanne L, Kim, Young Kyoon, Kirsner, Robert S, Lahiri, Koushik, Lamel, Sonia, Landau, Marina, Lane, Robert, Langdon, Robert C, Lawrence, Naomi, Lear, William, Lee, Ken K, Leffell, David J, Leitenberger, Justin J, Levin, Yakir, Levy, Ross M, Li, Jie, MacNeal, Robert J, Maggio, Kurt L, Mariwalla, Kavita, Messingham, Michael J, Miller, Christopher J, Morganroth, Greg S, Moy, Ronald L, Mysore, Venkataram, Na, Se Young, Ochoa, Shari Nemeth, Nilsson, Magnus B, Nguyen, Tri, Ozog, David, Pannier, Felizitas, Park, Kyoung Chan, Pasquali, Paola, Pavlović, Miloš D, Phillips, Tania J, Pop, Sebastian, Pritzker, Rachel N, Rabe, Eberhard, Redondo, Pedro, Reeder, Virginia J, Robinson, June K, Rohrer, Thomas E, Rusciani, Antonio, Rzany, Berthold, Saedi, Nazanin, Salavastru, Carmen, Sattler, Gerhard, Schuller-Petrovic, Sanja, Schulze, Rafael A, Siegel, Daniel M, Silapunt, Sirunya, Sobanko, Joseph F, Somoano, Brian, Soriano, Teresa T, Srivastava, Divya, Stebbins, William G, Swanson, Neil A, Taylor, R Stan, Tierney, Emily P, Travelute, Christie R, Troilus, Agneta, Tsao, Sandy S, Unger, Walter, Vidimos, Allison T, Weinstein, Mara C, and Yasuta, Masato
- Published
- 2016
157. Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne
- Author
-
Eichenfield, Lawrence F., primary, Krakowski, Andrew C., additional, Piggott, Caroline, additional, Del Rosso, James, additional, Baldwin, Hilary, additional, Friedlander, Sheila Fallon, additional, Levy, Moise, additional, Lucky, Anne, additional, Mancini, Anthony J., additional, Orlow, Seth J., additional, Yan, Albert C., additional, Vaux, Keith K., additional, Webster, Guy, additional, Zaenglein, Andrea L., additional, and Thiboutot, Diane M., additional
- Published
- 2013
- Full Text
- View/download PDF
158. Results of a Phase 2 Efficacy and Safety Study with SB204, an Investigational Topical Nitric Oxide-releasing Drug for the Treatment of Acne Vulgaris.
- Author
-
BALDWIN, HILARY, BLANCO, DAISY, MCKEEVER, CHARLES, PAZ, NELLY, VASQUEZ, YNCA NINA, QUIRING, JOHN, ENLOE, CAROLYN, DE LEÓN, EMILY, STASKO, NATHAN, and De León, Emily
- Subjects
- *
DRUG efficacy , *MEDICATION safety , *THERAPEUTIC use of nitric oxide , *SKIN disease treatment , *ACNE , *CLINICAL trials - Abstract
Objective: To compare efficacy, tolerability, and safety of two concentrations of topical SB204 and vehicle twice daily for 12 weeks in the treatment of acne vulgaris.Design: Randomized, double-blind, placebo-controlled, three-arm, Phase 2 study.Setting: Dominican Republic, Panama, and Honduras.Participants: Subjects with acne, age 12 to 40, with 25 to 70 noninflammatory lesions, 20 to 40 inflammatory lesions, and a baseline Investigator's Global Assessment score of mild, moderate, or severe.Measurements: The primary efficacy assessment was the absolute change in noninflammatory lesion counts. Other assessments included inflammatory lesion counts, success on dichotomized Investigator's Global Assessment, reported adverse events, physical examinations, laboratory testing, and tolerability.Results: One hundred fifty-three subjects were randomized to vehicle (n=52), SB204 1% (n=51), or SB204 4% (n=50). When compared to vehicle, subjects treated with SB204 1% and SB204 4% had significantly greater mean percent reduction in noninflammatory lesions from baseline and subjects treated with SB204 4% had a significantly greater mean percent reduction in inflammatory lesion count from baseline at Week 12. There were no significant differences in the IGA success rates between groups. Both concentrations of SB204 were safe and well-tolerated.Conclusions: When compared to vehicle, both SB204 1% and SB204 4% significantly decreased the percentage of noninflammatory lesions and SB204 4% also significantly decreased the percentage of inflammatory lesions in subjects with acne vulgaris treated for 12 weeks. Treatment with SB204 1% and SB204 4% was safe and well-tolerated. Registry: clinicaltrials.gov (NCT01844752). [ABSTRACT FROM AUTHOR]- Published
- 2016
159. Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females.
- Author
-
GOLD, LINDA STEIN, BALDWIN, HILARY, RUEDA, MARIA JOSE, KERROUCHE, NABIL, and DRÉNO, BRIGITTE
- Subjects
- *
ACNE , *SKIN disease treatment , *BENZOYL peroxide , *RETINOIDS , *DRUG efficacy , *ADOLESCENT health , *WOMEN'S health , *THERAPEUTICS - Abstract
Objectives: To evaluate the efficacy and safety of adapalene 0.1% benzoyl peroxide 2.5% gel in women aged 25 years or older via subgroup analysis of existing Phase 2 and 3 study data. Methods: Meta-analysis of pooled data from three multicenter, randomized, double-blind, vehicle-controlled, parallel-group, clinical trials compared results of treatment with either adapalene 0.1% benzoyl peroxide 2.5% gel or vehicle gel in adult females and teen-aged females. Efficacy assessments included investigator's global assessment and median percent change in acne lesions. Safety assessments included skin tolerability and adverse events. Results: Two hundred fifty-four adult females and 488 teen-aged females were included in the analyses, and baseline characteristics were comparable between subjects receiving adapalene 0.1% benzoyl peroxide 2.5% or vehicle. Both adult females and teen-aged females in the adapalene 0.1% benzoyl peroxide 2.5% arm were significantly more often rated clear/almost clear compared with those in the vehicle arm at Weeks 8 (P=0.016) and 12 (P<0.001); at endpoint, success was achieved in 39.2 percent with adapalene 0.1% benzoyl peroxide 2.5% and 18.5 percent with vehicle. Comparison of the amount of difference between active and vehicle reductions in investigator's global assessment showed that efficacy was similar for adult females versus teen-aged females (20.7% vs. 19.9%, respectively). Adapalene 0.1% benzoyl peroxide 2.5% had a rapid onset of action, with statistically significant reductions in all acne lesion types versus vehicle observed by Week 1. Adapalene 0.1% benzoyl peroxide 2.5% was safe and well-tolerated by adult females with a tolerability profile consistent with that seen in teen-aged females. Conclusions: The once-daily fixed-dose combination product adapalene 0.1% benzoyl peroxide 2.5% is an efficacious, safe, and well-tolerated treatment for adult female acne, with a profile similar to that in teen-aged females. [ABSTRACT FROM AUTHOR]
- Published
- 2016
160. Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From Two Phase III, Randomized, Vehicle-Controlled Trials.
- Author
-
BHATIA, NEAL D., WERSCHLER, WM. PHILIP, BALDWIN, HILARY, SUGARMAN, JEFFREY, GREEN, LAWRENCE J., LEVY-HACHAM, OFRA, NOV, ORI, RAM, VERED, and GOLD, LINDA STEIN
- Subjects
- *
BENZOYL peroxide , *CLINICAL trials , *ROSACEA , *ADVERSE health care events - Abstract
OBJECTIVE: A new formulation of benzoyl peroxide (E-BPO cream, 5%) entraps benzoyl peroxide (BPO) in silica microcapsules. This study assesses the efficacy, safety, and tolerability of E-BPO cream, 5%, in rosacea in two Phase III clinical trials. METHODS: In two 12-week, randomized, double- blind, vehicle cream-controlled Phase III trials, 733 subjects at least 18 years old with moderate to severe rosacea were randomized (2:1) to once-daily E-BPO cream, 5%, or vehicle. RESULTS: In Study 1, the proportion of subjects achieving IGA clear/almost clear at Week 12 was 43.5 percent for E-BPO cream, 5%, and 16.1 percent for vehicle. In Study 2, the respective values were 50.1 percent and 25.9 percent. In Study 1, the decrease in lesion count from baseline to Week 12 was -17.4 for E-BPO cream, 5%, versus -9.5 for vehicle. In Study 2, the respective values were -20.3 and -13.3 (all P<0.001). The difference was also significant at Week 2. There were no treatment-related serious adverse events; 1.4 percent of subjects (1.8% E-BPO cream, 5%, 0.4% vehicle) discontinued due to adverse events. Assessed local tolerability was found to be similar among subjects in both E-BPO and vehicle. LIMITATIONS: E-BPO was not compared with unencapsulated BPO. CONCLUSION: E-BPO is an effective and well tolerated treatment for rosacea. Clinicaltrials.gov Identifiers: NCT03564119, NCT03448939. [ABSTRACT FROM AUTHOR]
- Published
- 2023
161. List of Contributors
- Author
-
Aasi, Sumaira Z, Acosta, Alvaro E, Affleck, Andrew G, Alam, Murad, Amini, Sadegh, Arndt, Kenneth A, Arpey, Christopher J, Baldwin, Hilary, Bello, Ysabel, Berman, Brian, Bernstein, Robert M, Bhatia, Ashish C, Bolotin, Diana, Book, Samuel E, Breithaupt, Andrew, Breu, Franz X, Brown, Katherine L, Butterwick, Kimberly J, Cao, Theresa, Carney, J Michael, Cartee, Todd V, Chan, Henry Hin Lee, Chan, Johnny Chun Yin, Charles, Carlos A, Chesnut, Cameron, Colver, Graham, Cook, Jonathan L, Countryman, Nicholas B, Donofrio, Lisa M, Falabella, Anna F, Fernández-Obregón, Adolfo C, Fincher, Edgar F, Fratila, Alina, Ghannam, Sahar F, Gladstone, Hayes B, Glaser, Dee Anna, Goldberg, Leonard H, Goldman, Glenn D, Goldsberry, Anne, Goodman, Greg J, Greenway, Hubert T, Hamzavi, Iltefat, Haneke, Eckart, Hanke, C William, Hanlon, Allison, Hexsel, Camile L, Hexsel, Doris, Holmes, Todd E, Hruza, George J, Hsu, Jeffrey T S, Ibrahimi, Omar A, Isenhath, Scott N, Iyengar, Vivek, Kaminer, Michael S, Khachemoune, Amor, Khunger, Niti, Kilmer, Suzanne L, Kim, Young Kyoon, Kirsner, Robert S, Lahiri, Koushik, Lamel, Sonia, Landau, Marina, Lane, Robert, Langdon, Robert C, Lawrence, Naomi, Lear, William, Lee, Ken K, Leffell, David J, Leitenberger, Justin J, Levin, Yakir, Levy, Ross M, Li, Jie, MacNeal, Robert J, Maggio, Kurt L, Mariwalla, Kavita, Messingham, Michael J, Miller, Christopher J, Morganroth, Greg S, Moy, Ronald L, Mysore, Venkataram, Na, Se Young, Ochoa, Shari Nemeth, Nilsson, Magnus B, Nguyen, Tri, Ozog, David, Pannier, Felizitas, Park, Kyoung Chan, Pasquali, Paola, Pavlović, Miloš D, Phillips, Tania J, Pop, Sebastian, Pritzker, Rachel N, Rabe, Eberhard, Redondo, Pedro, Reeder, Virginia J, Robinson, June K, Rohrer, Thomas E, Rusciani, Antonio, Rzany, Berthold, Saedi, Nazanin, Salavastru, Carmen, Sattler, Gerhard, Schuller-Petrović, Sanja, Schulze, Rafael A, Siegel, Daniel M, Silapunt, Sirunya, Sobanko, Joseph F, Somoano, Brian, Soriano, Teresa T, Srivastava, Divya, Stebbins, William G, Swanson, Neil A, Taylor, R Stan, Tierney, Emily P, Travelute, Christie R, Troilus, Agneta, Tsao, Sandy S, Unger, Walter, Vidimos, Allison T, Weinstein, Mara C, and Yasuta, Masato
- Published
- 2015
- Full Text
- View/download PDF
162. The Bright Side of iPLEDGE
- Author
-
BALDWIN, HILARY E., primary
- Published
- 2006
- Full Text
- View/download PDF
163. Answers to Self-Assessment examination of the American Academy of DermatologyIdentification No. 800-207
- Author
-
Baldwin, Hilary E., primary, Salasche, Stuart J., additional, Khachemoune, Amor, additional, Stefanato, Catherine M., additional, and Phillips, Tania J., additional
- Published
- 2000
- Full Text
- View/download PDF
164. Best practices in: treating rosacea--a focus on Axelaic Acid
- Author
-
Baldwin, Hilary E.
- Subjects
Medical research ,Medicine, Experimental ,Skin diseases -- Diagnosis ,Chronic diseases -- Diagnosis ,Health - Abstract
Rosacea: A Common, Chronic Condition Skin disease is commonly seen in the primary care setting. A 2-year chart review conducted at the University of Miami reported that 36.5% of patients [...]
- Published
- 2010
165. Lasting immunity to varicella in doctors study (L.I.V.I.D. study)
- Author
-
Solomon, Barry A., primary, Kaporis, Athena G., additional, Glass, Alan T., additional, Simon, Steven I., additional, and Baldwin, Hilary E., additional
- Published
- 1998
- Full Text
- View/download PDF
166. Treatment of Porokeratosis of Mibelli with CO2Laser Vaporization Versus Surgical Excision with Split-Thickness Skin Graft
- Author
-
RABBIN, PHOEBE E., primary and BALDWIN, HILARY E., additional
- Published
- 1993
- Full Text
- View/download PDF
167. Brunsting-Perry Cicatricial Pemphigoid Precipitated by Trauma
- Author
-
Baldwin, Hilary, primary
- Published
- 1991
- Full Text
- View/download PDF
168. Dumbbells for Dummies: A Simplified Approach to Managing Dumbbell-shaped Keloids of the Earlobe.
- Author
-
MARSON, JUSTIN W. and BALDWIN, HILARY E.
- Subjects
- *
KELOIDS , *DUMBBELLS , *MEDICAL offices , *WOUND healing - Abstract
BACKGROUND: Keloids are dense, fibrous tumors that arise from the dysregulation of normal wound healing, ultimately outgrowing the initial traumatic lesion. OBJECTIVE: We present a modified technique for the excision of dumbbell-shaped keloids on the earlobe using tools common to every dermatologist's office. METHODS: This was an observational report on the outcomes of dumbbell keloid excision using a #15 blade and punch biopsy. Eligible individuals were those with dumbbell-shaped keloids located on the earlobe. All procedures were conducted at an urban dermatology clinic. RESULTS: When combining the technique with continual compression earrings and intralesional corticosteroids, excellent cosmetic outcomes and minimal recurrence were achieved. CONCLUSION: The pairing of a #15 blade and punch biopsy has been demonstrated to produce a more user-friendly method for dumbbell keloid excision by dermatologists and clinicians without advanced surgical training. [ABSTRACT FROM AUTHOR]
- Published
- 2020
169. The Treatment of Zoon's Balanitis with the Carbon Dioxide Laser.
- Author
-
Baldwin, Hilary E. and Geronemus, Roy G.
- Abstract
Zoon's balanitis, or plasma cell balanitis, is a chronic erosive process of the uncircumcised penis. The lesions are often refractory to conservative topical and surgical therapy and frequently require circumcision as a curative measure. This case report describes the first reported successful use of the carbon dioxide laser in the defocused mode to vaporize the chronic penile erosions of Zoon's balanitis. [ABSTRACT FROM AUTHOR]
- Published
- 1989
- Full Text
- View/download PDF
170. Schools of the Future.
- Author
-
Baldwin, Hilary
- Published
- 1967
- Full Text
- View/download PDF
171. Correction to: Effects of Diet on Acne and Its Response to Treatment.
- Author
-
Baldwin, Hilary and Tan, Jerry
- Subjects
- *
ACNE , *TREATMENT effectiveness - Abstract
The original article can be found online. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
172. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
- Author
-
Kircik, Leon H., Stein Gold, Linda, Gold, Michael, Weiss, Jonathan S., Harper, Julie C., Del Rosso, James Q., Bunick, Christopher G., Bhatia, Neal, Tanghetti, Emil A., Eichenfield, Lawrence F., Baldwin, Hilary, Draelos, Zoe D., Callender, Valerie D., Han, George, Gooderham, Melinda J., Sadick, Neil, Lupo, Mary P., Lain, Edward, and Werschler, William Philip
- Subjects
- *
ACNE , *CLINDAMYCIN , *PEROXIDES , *DRUG resistance in bacteria , *PHOSPHATES , *SEBORRHEIC dermatitis - Abstract
Introduction: A three-pronged approach to acne treatment combining an antibiotic, antimicrobial, and retinoid may be more efficacious than single/double treatments while potentially reducing antibiotic resistance. This study evaluated the efficacy and safety of the first fixed-dose, triple-combination topical acne product, clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB) using pooled phase 3 data. Methods: In two identical phase 3 (N = 183; N = 180), double-blind, 12-week studies, participants aged ≥ 9 years with moderate-to-severe acne were randomized 2:1 to receive once-daily CAB or vehicle gel. Endpoints included ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score and clear/almost clear skin (treatment success) and least-squares mean percent change from baseline in acne lesion counts. Treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were evaluated. Results: At week 12, 50.0% of participants achieved treatment success with CAB versus 22.6% with vehicle gel (P < 0.001). CAB resulted in > 70% reductions in inflammatory and noninflammatory lesions at week 12 (77.9% and 73.0%, respectively), which were significantly greater than vehicle (57.9% and 48.2%; P < 0.001, both). Most TEAEs were of mild-moderate severity, and < 3% of CAB-treated participants discontinued study/treatment because of AEs. Transient increases from baseline in scaling, erythema, itching, burning, and stinging were observed with CAB, but resolved back to or near baseline values by week 12. Conclusions: The innovative fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel was efficacious and well tolerated in children, adolescents, and adults with moderate-to-severe acne. Half of participants achieved clear/almost clear skin by 12 weeks, rates not previously seen in clinical studies of other topical acne products. Trial Registration: ClinicalTrials.gov identifier NCT04214639 and NCT04214652. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
173. Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae from the Personalising Acne: Consensus of Experts
- Author
-
Layton, Alison, Alexis, Andrew, Baldwin, Hilary, Beissert, Stefan, Bettoli, Vincenzo, Del Rosso, James, Dréno, Brigitte, Stein Gold, Linda, Harper, Julie, Lynde, Charles, Thiboutot, Diane, Weiss, Jonathan, and Tan, Jerry
- Abstract
The physical sequelae of acne include erythema, hyperpigmentation, and scarring, which are highly burdensome for patients. Early, effective treatment can potentially limit and prevent sequelae development, but there is a need for guidance and evidence on prevention-oriented management to improve patient outcomes.
- Published
- 2021
- Full Text
- View/download PDF
174. Minocycline Extended-Release Comparison with Doxycycline for the Treatment of Rosacea: A Randomized, Head-to-Head, Clinical Trial.
- Author
-
TSIANAKAS, ATHANASIOS, PIEBER, THOMAS, BALDWIN, HILARY, FEICHTNER, FRANZ, ALIKUNJU, SHANAVAS, GAUTAM, ANIRUDH, SHENOY, SRINIVAS, SINGH, PREETI, and SIDGIDDI, SRINIVAS
- Subjects
- *
DOXYCYCLINE , *ROSACEA , *MINOCYCLINE , *CLINICAL trials , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Objective: Minocycline efficacy for the treatment of papulopustular rosacea (PPR) has not been evaluated in clinical trials at levels demonstrated to stay below the antimicrobial threshold. We assessed the efficacy, safety, and dose response of DFD-29, a minocycline extended-release oral capsule. Two studies are reported (NCT03340961).Methods: A single-center open-label, three-arm, Phase I pharmacokinetic study randomized 24 healthy subjects aged 18 to 45 years to receive 21 days of once-daily dosing with DFD-29 40 or 20mg, or doxycycline 40mg. Blood samples were collected over 24 hours on Days 1 and 21 to plot mean plasma concentration levels. A multicenter Phase II clinical trial randomized 205 subjects with mild-to-severe PPR 1:1:1:1 to receive once-daily DFD-29 40 or 20mg, doxycycline 40mg, or placebo for 16 weeks. Co-primary endpoints were the proportion of subjects achieving treatment success (IGA grade 0 or 1 and ≥2-grade improvement) at Week 16, and a reduction in total inflammatory lesion count at Week 16.Results: Pharmacokinetic analysis demonstrated that minocycline plasma levels of DFD-29 40mg were approximately half those of doxycycline 40mg after 21 days, with DFD-29 20mg even lower, demonstrating a dose response. In the Phase II trial, DFD-29 40mg met both co-primary endpoints, achieving IGA treatment success in 66.0 percent subjects versus 11.5 percent placebo (p<0.0001), 31.9 percent DFD-29 20mg (p=0.007), and 33.3 percent doxycycline 40mg (p<0.0010), and a mean reduction in lesion counts of -19.2 versus -7.3 placebo (p<0.0001), -12.6 DFD-29 20mg (p=0.0070), and -10.5 doxycycline 40mg (p=0.0004).Limitations: MIC values and plasma concentrations shown for antibacterial threshold data are mean values; fast absorbers/slow metabolizers could exceed the threshold, causing resistance selection pressure.Conclusion: DFD-29 40mg demonstrated significantly greater efficacy than placebo, DFD-29 20mg, and doxycycline 40mg at plasma concentrations predicted to be below the antimicrobial threshold for the treatment of PPR. [ABSTRACT FROM AUTHOR]- Published
- 2021
175. LASERS: The Treatment of Zoon's Balanitis with the Carbon Dioxide Laser
- Author
-
BALDWIN, HILARY E., primary and GERONEMUS, ROY G., additional
- Published
- 1989
- Full Text
- View/download PDF
176. Severe Recalcitrant Nodular Acne -- Treatment Update on Safety and Efficacy.
- Author
-
Baldwin, Hilary E. and Orlow, Seth J.
- Subjects
DRUG efficacy ,ISOTRETINOIN ,ACNE ,SKIN disease treatment ,ANTIBIOTICS - Abstract
The article presents an update on the continuing educational activity regarding the safety and efficacy of isotretinoin as treatment for severe recalcitrant nodular acne. Isotretinoin is the only U.S. Food and Drug Administration (FDA) approved agent for the treatment of the condition, specifically for those who are unresponsive to systemic antibiotics. The drug dosage varies with every patient but most patients show a high level of adherence to the medication.
- Published
- 2008
177. Reddit dermatology: a cross‐sectional analysis of the r/acne forum.
- Author
-
Richardson, William M., Marson, Justin W., Chen, Rebecca M., Shah, Jill T., and Baldwin, Hilary E.
- Subjects
- *
ACNE , *CROSS-sectional method , *DERMATOLOGISTS , *WORLD Wide Web - Abstract
This article examines the content and quality of discussions about acne on the r/acne subreddit on Reddit. The study analyzed posts and comments from the subreddit to assess public knowledge and awareness of acne based on American Academy of Dermatology (AAD) guidelines. The findings showed that while the community displayed some degree of acne health literacy, there was a prevalence of incomplete and potentially questionable information. Additionally, a minority of comments recommended seeing a dermatologist, which could lead to misinformation and potentially harm patients. The study suggests the need for improved counseling and health outcomes among acne patients and further research on health literacy in dermatology communities. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
178. Long-term Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From an Extension of Two Phase Ill, Vehicle-controlled Trials.
- Author
-
WERSCHLER, WILLIAM P., SUGARMAN, JEFFREY, BHATIA, NEAL, BALDWIN, HILARY, GREEN, LAWRENCE J., NOV, ORI, RAM, VERED, LEVY-HACHAM, OFRA, and STEIN-GOLD, LINDA
- Subjects
- *
BENZOYL peroxide , *ROSACEA , *ADVERSE health care events - Abstract
OBJECTIVE: We sought to assess the long-term safety and tolerability of microencapsulated benzoyl peroxide cream, 5% (E-BPO cream, 5%), in 7 subjects with rosacea. Efficacy and tolerability have been previously demonstrated in two 12-week, randomized, double-blind, vehicle-controlled Phase Ill trials. METHODS: In this open-label extension study (NCT03564145; clinicaltrials.gov), all subjects from the initial placebo-controlled Phase Ill trials could receive E-BPO cream, 5%, for up to an additional 40 weeks, up to a total of 52 weeks of E-BPO cream, 5%, exposure. If a subject was assessed at study visits as "clear' or "almost clear' using the 5-point Investigator Global Assessment (IGA) scale (IGA O or 1), E-BPO cream, 5%, was not dispensed. If a subject was assessed as "mild to severe" (IGA 2+ ), E-BPO cream, 5%, was applied daily until they reached "clear' or "almost clear:' RESULTS: The safety and tolerability profile for E-BPO cream, 5%, was similar to that reported in the Phase Il l studies. Five subjects (0.9%) discontinued study drug due to treatment-related adverse events, and 17 subjects (3.2%) experienced an adverse event considered related to study drug. I GA success after 40 weeks of active treatment was 66.5 percent for subjects continuing from the Phase Il l vehicle group (n= 172) and 67.6 percent for subjects who continued Phase Ill E-BPO cream, 5% (n=363). The study ended early in accordance with the protocol. LIMITATIONS: Safety and tolerability of E-BPO were not compared with those of unencapsulated BPO. CONCLUSION: E-BPO cream, 5%, showed a favorable safety and tolerability profile during this 40-week, open-label extension study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
179. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
- Author
-
Eichenfield, Lawrence F., Gold, Linda Stein, Kircik, Leon H., Werschler, William P., Beer, Kenneth, Draelos, Zoe D., Tanghetti, Emil A., Papp, Kim A., Baldwin, Hilary, Lain, Edward, Sadick, Neil, Gooderham, Melinda J., and Konda, Adarsh
- Subjects
- *
ACNE , *TEENAGERS , *CLINDAMYCIN , *PEROXIDES , *QUALITY of life , *HYPERPHOSPHATEMIA - Abstract
Background/Objectives: Topical clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) is the first fixed-dose triple-combination formulation in development for acne. This post hoc analysis investigated efficacy and safety of IDP-126 in children and adolescents with moderate-to-severe acne. Methods: In a randomized, double-blind phase 2 study (NCT03170388), participants ≥9 years of age with moderate-to-severe acne were eligible for randomization (1:1:1:1:1) to once-daily IDP-126, one of three dyad combination gels, or vehicle gel for 12 weeks. This post hoc analysis of pediatric participants (n = 394) included children and adolescents up to 17 years of age. Assessments included treatment success, inflammatory/ noninflammatory lesion counts, Acne-Specific Quality of Life (Acne-QoL) questionnaire, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability. Results: At Week 12, treatment success rates were significantly greater with IDP126 (55.8%) than with vehicle (5.7%; p < .001) or any of the dyad combinations (range: 30.8%–33.9%; p < .01, all). Lesion reductions with IDP-126 were also significantly greater than with vehicle (inflammatory: 78.3% vs. 45.1%; noninflammatory: 70.0% vs. 37.6%; p < .001, both) and 9.2%–16.6% greater than with any of the dyad combinations. Increases (improvements) from baseline in Acne-QoL domain scores were generally greater with IDP-126 than in any other treatment group. The most common treatment-related TEAEs across treatment groups were application site pain and dryness. Most treatment-related TEAEs were of mild-to-moderate severity. Conclusion: IDP-126 gel—a novel fixed-dose, triple-combination topical formulation for acne—demonstrated superior efficacy to vehicle and three dyad component gels and was well tolerated in children and adolescents with moderate-to-severe acne. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
180. Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.
- Author
-
Keri, Jonette, Cook-Bolden, Fran E., Green, Lawrence, Kircik, Leon H., Baldwin, Hilary, Werschler, William Philip, Guenin, Eric, Pillai, Radhakrishnan, and Bhatt, Varsha
- Subjects
- *
BODY mass index , *ACNE , *OBESITY , *BENZOYL peroxide , *TRETINOIN - Abstract
Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese). Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20–25% were overweight and 15–20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: −63.2%, obese: −56.0%); tretinoin (−57.6%, −53.1%); tazarotene (−59.9%, −56.8%). Mean changes in noninflammatory lesions were: CP/BPO (−54.2%, −50.8%); tretinoin (−51.6%, −44.9%); tazarotene (−56.7%, −54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups. CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
181. Chapter 44 - Keloid Management
- Author
-
Baldwin, Hilary
- Full Text
- View/download PDF
182. List of Contributors
- Author
-
Aasi, Sumaira Z, Alster, Tina S, Ammirati, Christie T, Anderson, E Ratcliffe, Jr, Arndt, Kenneth A, Arpey, Christopher J, Baldwin, Hilary, Berg, Daniel, Bernstein, Robert M, Bhatia, Ashish C, Bogle, Melissa A, Book, Samuel E, Butterwick, Kimberly J, Carney, J Michael, Carruthers, Alastair, Carruthers, Jean, Carucci, John A, Castro-Ron, Gilberto, Charles, Carlos A, Christensen, Dane R, Coldiron, Brett M, Cook, Joel, Cook, Jonathan L, Cox, Sue Ellen, Davey, W Patrick, Dinehart, Scott M, Donofrio, Lisa M, Drugge, Rhett J, Falabella, Anna F, Fein, Howard, Fernández-Obregón, Adolfo C, Fincher, Edgar F, Fish, Frederick S, III, Garcia, Carlos, Gladstone, Hayes B, Glaser, Dee Anna, Goldberg, Leonard H, Goldman, Glenn D, Goldman, Mitchel P, Gorman, Annalisa K, Greenway, Hubert T, Haas, Ann F, Halpern, Allan C, Haneke, Eckart, Hanke, C William, Harmon, Christopher B, Hruza, George J, Huang, Carol L, Iyengar, Vivek, Jacob, Carolyn I, Joseph, Aaron K, Kaminer, Michael S, Kauvar, Arielle NB, Kirsner, Robert S, Krant, Jessica J, Langdon, Robert C, Lask, Gary P, Lawrence, Naomi, Lawry, Monica, Layman, Jason, Lee, Ken K, Leffell, David J, Leonhardt, Janie M, Leveriza-Oh, May, Li, Jie, Maggio, Kurt L, Maloney, Mary, Marghoob, Ashfaq A, Mason, Camille L, Moody, Brent R, Moy, Ronald L, Naylor, Mark, Nguyen, Tri H, Pasquali, Paola, Phillips, Tania J, Pollack, Sheldon V, Robinson, June K, Rohrer, Thomas E, Sattler, Gerhard, Sengelmann, Roberta D, Siegel, Daniel Mark, Silapunt, Sirunya, Soon, Seaver L, Soriano, Teresa T, Spencer, James M, Squires, Jeffrey A, Stasko, Thomas, Swanson, Neil A, Tanzi, Elizabeth L, Taylor, R Stan, Troilius, Agneta, Tsao, Sandy S, Tull, Stacey, Vidimos, Allison T, Washington, Carl V, Jr, Weber, Paul J, Weiss, Robert A, Weitzul, Sarah, Whitaker, Duane C, and Zitelli, John A
- Full Text
- View/download PDF
183. A Cosmetic Regimen Formulated to Address the Multi-Modal Pathogenesis of Rosacea Demonstrates Efficacy for Treating Facial Redness and Skin's Appearance.
- Author
-
Farris PK, Gerstein FH, Baldwin HE, and Draelos ZD
- Subjects
- Humans, Female, Middle Aged, Adult, Male, Treatment Outcome, Erythema drug therapy, Erythema etiology, Sunscreening Agents administration & dosage, Aged, Face, Administration, Cutaneous, Rosacea drug therapy, Rosacea diagnosis
- Abstract
Background: The treatment of rosacea is complicated as there are multiple pathogenic factors in play resulting in a myriad of clinical signs and symptoms including facial redness., Objective: The primary objective was to evaluate the efficacy and tolerability of a non-prescription anti-redness regimen in patients with rosacea., Methods: Thirty subjects with rosacea-induced facial erythema were enrolled in this single site, monadic study. The test regimen consisted of a treatment serum, redness-reducing moisturizer, and sunscreen. The test products are formulated with ingredients curated to address the multifactorial pathogenesis of facial redness. Investigator and subject self-assessment for efficacy and tolerability were performed at baseline, weeks 4 and 8. Non-invasive assessments for facial redness and skin hydration were conducted at all time points., Results: Investigator grading showed significant improvement in facial redness of 21% at week 4 and 32% at week 8. Skin's appearance improved as early as 4 weeks while at 8 weeks there was statistically significant improvement in fine lines 15%, radiance/brightness 37%, tactile roughness 44%, visual roughness 41%, and 26% in overall appearance. Non-invasive assessments showed statistically significant improvement in skin hydration of 28% at week 4 and facial redness of 21% by week 8. No tolerability issues were identified by the investigator., Conclusion: Patients with rosacea often turn to over-the-counter products to reduce facial redness and improve skin's appearance. In this study, a cosmetic skincare regimen designed to reduce facial redness demonstrated efficacy and tolerability in subjects with rosacea. J Drugs Dermatol. 2024;23(9):757-763. doi:10.36849/JDD.8460.
- Published
- 2024
- Full Text
- View/download PDF
184. Challenges in Adult Acne and the Role of Skin Care in Managing the Condition.
- Author
-
Baldwin HE, Ablon G, Callender V, Farris PK, Lain T, Rieder EA, Schlesinger T, Marson J, Andriessen A, and Woolery-Lloyd H
- Subjects
- Humans, Adult, Dermatologic Agents administration & dosage, Dermatologic Agents therapeutic use, Female, Delphi Technique, Consensus, Acne Vulgaris therapy, Acne Vulgaris drug therapy, Skin Care methods
- Abstract
Background: Acne vulgaris is a complex, multifactorial, inflammatory skin condition. Although frequently presented at dermatology clinics, the literature on adult acne is scarce, particularly concerning skin barrier function and management. We aimed to provide insights into the role of skin barrier integrity in adult acne patients and the role of cleansers and moisturizers as adjunctive to treating and maintaining adult acne. Methods: A panel of eight dermatologists who treat adult patients with acne developed a consensus paper on the role of skin barrier function and skin care in adult acne management. The modified Delphi method comprised a face-to-face meeting and online follow-up to discuss the results of a scoping literature review. Drawing from their experience and opinions, they agreed on seven consensus statements. Results: Epidermal barrier dysfunction plays a vital role in acne pathogenesis and asymmetrically impacts adult female acne. Erythema, pruritus, peeling, and xerosis are common adverse effects of first-line acne treatment options and, if not appropriately counseled and managed, can exacerbate, leading to regimen nonadherence and poor patient experience and outcomes., Conclusion: Improving patient knowledge of comprehensive acne treatments, including quality adjunctive cleansers and moisturizers, may maximize regimen efficacy and provide patients with personalized and successful acne treatment and maintenance tools. J Drugs Dermatol. 2024;23(8):674-679. doi:10.36849/JDD.8471.
- Published
- 2024
- Full Text
- View/download PDF
185. Going Beyond Ceramides in Moisturizers: The Role of Natural Moisturizing Factors.
- Author
-
Baldwin H and Del Rosso J
- Subjects
- Humans, Skin Cream administration & dosage, Administration, Cutaneous, Epidermis drug effects, Epidermis metabolism, Epidermis physiology, Urea administration & dosage, Ceramides administration & dosage, Water Loss, Insensible drug effects, Emollients administration & dosage
- Abstract
Xerosis is experienced by almost everyone at some time in their lives and the foundation of management of dry skin (both consumer- and healthcare professional--directed) rests on the use of moisturizers. Given the wide range of available moisturizers, counseling patients about selecting the optimum moisturizer for their individual situation relies on knowledge of ingredients and formulations. Traditionally, the main focus for many moisturizers centered on the core functional and structural role of ceramides within the epidermal barrier. However, while a key aspect of transepidermal water loss and other skin barrier functions, components other than ceramides are equally essential in increasing moisturization. The skin's natural moisturizing factors (NMFs) are a complex mixture of water-attracting compounds such as amino acids, urea, lactate, pyrrolidone carboxylic acid (PCA), and electrolytes which play a fundamental role in preserving physiologic function by regulating the water content of the stratum corneum. By facilitating water retention, NMFs contribute significantly to the suppleness, elasticity, normal desquamation, and overall integrity of the skin barrier. Incorporation of NMFs into moisturizers addresses critical deficiencies in the skin's moisture balance that exist in xerotic and atopic skin, and in many skin disorders, mitigating signs and symptoms associated with xerosis and promoting optimal skin health. The biochemical composition of NMFs and the intricate interplay with epidermal homeostasis translate to a central role in moisturizers used for prophylactic and therapeutic management of various dry skin conditions, beyond ceramides alone. J Drugs Dermatol. 2024;23(6):466-471. doi:10.36849/JDD.8358.
- Published
- 2024
- Full Text
- View/download PDF
186. Rosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement.
- Author
-
Dirr MA, Ahmed A, Schlessinger DI, Haq M, Shi V, Koza E, Ma M, Christensen RE, Ibrahim SA, Schmitt J, Johannsen L, Asai Y, Baldwin HE, Berardesca E, Berman B, Vieira AC, Chien AL, Cohen DE, Del Rosso JQ, Dosal J, Drake LA, Feldman SR, Fleischer AB Jr, Friedman A, Graber E, Harper JC, Helfrich YR, Jemec GB, Johnson SM, Katta R, Lio P, Maier LE, Martin G, Nagler AR, Neuhaus IM, Palamar M, Parish LC, Rosen T, Shumack SP, Solomon JA, Tanghetti EA, Webster GF, Weinkle A, Weiss JS, Wladis EJ, Maher IA, Sobanko JF, Cartee TV, Cahn BA, Alam M, Kang BY, Iyengar S, Anvery N, Alpsoy E, Bewley A, Dessinioti C, Egeberg A, Engin B, Gollnick HPM, Ioannides D, Kim HS, Lazaridou E, Li J, Lim HG, Micali G, de Oliveira CMM, Noguera-Morel L, Parodi A, Reinholz M, Suh DH, Sun Q, van Zuuren EJ, Wollina U, Zhou Y, Zip C, Poon E, and Pearlman R
- Subjects
- Humans, Outcome Assessment, Health Care standards, Treatment Outcome, Rosacea therapy, Rosacea diagnosis, Clinical Trials as Topic standards, Consensus, Delphi Technique
- Abstract
Importance: Inconsistent reporting of outcomes in clinical trials of rosacea is impeding and likely preventing accurate data pooling and meta-analyses. There is a need for standardization of outcomes assessed during intervention trials of rosacea., Objective: To develop a rosacea core outcome set (COS) based on key domains that are globally relevant and applicable to all demographic groups to be used as a minimum list of outcomes for reporting by rosacea clinical trials, and when appropriate, in clinical practice., Evidence Review: A systematic literature review of rosacea clinical trials was conducted. Discrete outcomes were extracted and augmented through discussions and focus groups with key stakeholders. The initial list of 192 outcomes was refined to identify 50 unique outcomes that were rated through the Delphi process Round 1 by 88 panelists (63 physicians from 17 countries and 25 patients with rosacea in the US) on 9-point Likert scale. Based on feedback, an additional 11 outcomes were added in Round 2. Outcomes deemed to be critical for inclusion (rated 7-9 by ≥70% of both groups) were discussed in consensus meetings. The outcomes deemed to be most important for inclusion by at least 85% of the participants were incorporated into the final core domain set., Findings: The Delphi process and consensus-building meetings identified a final core set of 8 domains for rosacea clinical trials: ocular signs and symptoms; skin signs of disease; skin symptoms; overall severity; patient satisfaction; quality of life; degree of improvement; and presence and severity of treatment-related adverse events. Recommendations were also made for application in the clinical setting., Conclusions and Relevance: This core domain set for rosacea research is now available; its adoption by researchers may improve the usefulness of future trials of rosacea therapies by enabling meta-analyses and other comparisons across studies. This core domain set may also be useful in clinical practice.
- Published
- 2024
- Full Text
- View/download PDF
187. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.
- Author
-
Baldwin H, Gold LS, Harper JC, Alexis AF, Callender VD, Kircik L, Guenin E, and Eichenfield LF
- Subjects
- Humans, Child, Double-Blind Method, Adolescent, Female, Male, Adult, Treatment Outcome, Young Adult, Administration, Cutaneous, Severity of Illness Index, Acne Vulgaris drug therapy, Clindamycin administration & dosage, Clindamycin adverse effects, Clindamycin analogs & derivatives, Gels, Drug Combinations, Benzoyl Peroxide administration & dosage, Benzoyl Peroxide adverse effects, Dermatologic Agents administration & dosage, Dermatologic Agents adverse effects, Quality of Life
- Abstract
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This post hoc analysis investigated the efficacy and safety of CAB in pediatric (<18 years) and adult (greater than or equal to 18 years) participants., Methods: In two multicenter, double-blind, phase 3 studies (NCT04214639 and NCT04214652), participants greater than or equal to 9 years of age with moderate-to-severe acne were randomized (2:1) to 12 weeks of once-daily treatment with CAB or vehicle gel. Pooled data were analyzed for pediatric and adult subpopulations. Assessments included treatment success (greater than or equal to 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear], inflammatory/noninflammatory lesion counts, Acne-Specific Quality of Life (Acne-QoL) questionnaire, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability., Results: At week 12, treatment success rates for both pediatric and adult participants were significantly greater with CAB (52.7%; 45.9%) than with vehicle (24.0%; 23.5%; P<0.01, both). CAB-treated participants in both subgroups experienced greater reductions from baseline versus vehicle in inflammatory (pediatric: 78.6% vs 50.4%; adult: 76.6% vs 62.8%; P<0.001, both) and noninflammatory lesions (pediatric: 73.8% vs 41.1%; adult: 70.7% vs 52.2%; P<0.001, both). Acne-QoL improvements from baseline to week 12 were significantly greater with CAB than with a vehicle. Most TEAEs were of mild-to-moderate severity; no age-related trends for safety/tolerability were observed. Conclusions: CAB gel demonstrated comparable efficacy, quality of life improvements, and safety in pediatric and adult participants with moderate-to-severe acne. As the first fixed-dose, triple-combination topical formulation, CAB represents an important new treatment option for patients with acne. J Drugs Dermatol. 2024;23(6):394-402. doi:10.36849/JDD.8357.
- Published
- 2024
- Full Text
- View/download PDF
188. Acne microbiome: From phyla to phylotypes.
- Author
-
Dreno B, Dekio I, Baldwin H, Demessant AL, Dagnelie MA, Khammari A, and Corvec S
- Subjects
- Humans, Skin microbiology, Dysbiosis, Anti-Bacterial Agents, Propionibacterium acnes physiology, Acne Vulgaris therapy, Microbiota, Dermatitis
- Abstract
Acne vulgaris is a chronic inflammatory skin disease with a complex pathogenesis. Traditionally, the primary pathophysiologic factors in acne have been thought to be: (1) altered sebum production, (2) inflammation, (3) excess keratinization and (4) colonization with the commensal Cutibacterium acnes. However, the role of C. acnes has been unclear, since virtually all adults have C. acnes on their skin yet not all develop acne. In recent years, understanding of the role of C. acnes has expanded. It is still acknowledged to have an important place in acne pathogenesis, but evidence suggests that an imbalance of individual C. acnes phylotypes and an alteration of the skin microbiome trigger acne. In addition, it is now believed that Staphylococcus epidermidis is also an actor in acne development. Together, C. acnes and S. epidermidis maintain and regulate homeostasis of the skin microbiota. Antibiotics, which have long been a staple of acne therapy, induce cutaneous dysbiosis. This finding, together with the long-standing public health edict to spare antibiotic use when possible, highlights the need for a change in acne management strategies. One fertile direction of study for new approaches involves dermocosmetic products that can support epidermal barrier function and have a positive effect on the skin microbiome., (© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
189. Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis.
- Author
-
Harper JC, Baldwin H, Choudhury SP, Rai D, Ghosh B, Aman MS, Choudhury AR, Dutta SK, Dey D, Bhattacharyya S, Lin T, Joseph G, Dashputre AA, and Tan JKL
- Subjects
- Humans, Treatment Outcome, Administration, Cutaneous, Drug Combinations, Clindamycin administration & dosage, Clindamycin therapeutic use, Administration, Oral, Acne Vulgaris drug therapy, Acne Vulgaris diagnosis, Severity of Illness Index, Network Meta-Analysis, Randomized Controlled Trials as Topic, Dermatologic Agents administration & dosage, Dermatologic Agents therapeutic use
- Abstract
Background: Multiple treatment options exist for the management of moderate-to-severe acne. However, the comparative effectiveness (efficacy/safety) of moderate-to-severe acne treatments has not been systematically examined., Methods: A systematic literature review (SLR) was conducted to identify randomized controlled trials of ≥4 weeks of treatment (topical, oral, physical, or combinations) for moderate-to-severe facial acne in patients aged ≥9 years. Efficacy outcomes included: percentage of patients achieving ≥2-grade reduction from baseline and “clear” or “almost clear” for global severity score (treatment success); absolute change in inflammatory (ILs reduction); and noninflammatory lesion counts (NILs reduction). A random-effects network meta-analysis (NMA) was conducted for the efficacy outcomes. Treatments were ranked with posterior rank plots and surface under cumulative ranking values. Results: Eighty-five studies were included in the SLR/NMA. Topical triple-agent fixed-dose combination (FDC) gel (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) and combinations of double-agent fixed-dose topical treatments with oral antibiotics (TOA3) consistently ranked in the top 3 treatments. Topical triple-agent FDC gel was numerically superior to TOA3 for treatment success (log-odds ratios: 1.84 [95% credible interval (CrI) 1.36 to 2.29]) and 1.69 (95% CrI: 1.01 to 2.32) vs placebo/vehicle). TOA3 was numerically superior to topical triple-agent FDC gel for reduction of ILs (mean difference: -8.21 [-10.33 to -6.13]) and -10.40 [-13.44 to -7.14] vs placebo/vehicle) and NILs (mean difference: -13.41 [-16.69 to -10.32] and -17.74 [-22.56 to -12.85] vs placebo/vehicle)., Conclusions: Based on this SLR/NMA, topical triple-agent FDC gel was the most efficacious and safe treatment for moderate-to-severe acne. J Drugs Dermatol. 2024;23(4): doi:10.36849/JDD.8148.
- Published
- 2024
- Full Text
- View/download PDF
190. Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.
- Author
-
Harper JC, Kircik LH, Gold M, Hebert AA, Sugarman JL, Green L, Gold LS, Baldwin H, Guenin E, and DelRosso JQ
- Subjects
- Humans, Anti-Bacterial Agents administration & dosage, Child, Acne Vulgaris diagnosis, Acne Vulgaris drug therapy, Adapalene, Benzoyl Peroxide Drug Combination, Clindamycin administration & dosage
- Abstract
Background: A once-daily, three-pronged approach using an antibiotic, antibacterial, and retinoid may provide faster acne improvement versus monotherapy or dual-combination products. This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel—the first FDA-approved triple-combination topical acne product—to its dyads and vehicle., Methods: Phase 2 (N=741; NCT03170388) and phase 3 (N=183; N=180; NCT04214639; NCT04214652), double-blind, 12-week studies randomized participants aged ≥9 years with moderate-to-severe acne to once-daily CAB or vehicle gel; the phase 2 study included three additional dyad gel arms. The pooled percentage of participants achieving ≥33%, ≥50%, and ≥75% reduction in inflammatory and noninflammatory acne lesions was evaluated., Results: As early as week 4 in the phase 2 study, ≥33% reduction in inflammatory lesions occurred in a significantly greater percentage of CAB gel-treated participants (82.7%) than with the 3 dyads and vehicle (61.1-69.8%; P<0.05, all). These early reductions were sustained throughout the study, with significantly (P<0.05) more CAB-treated participants achieving ≥50% reduction in inflammatory lesions versus dyads and vehicle from weeks 4-12. By week 12, CAB led to substantial reductions of ≥75% in significantly more participants than dyads and vehicle (65.8% vs 49.9-51.2% and 21.6%; P<0.05, all). Similar trends were observed for noninflammatory lesions in the phase 2 study and for inflammatory and noninflammatory lesions in the phase 3 studies., Conclusions: Lesion count reductions were significantly greater with CAB versus its dyads and vehicle gel as early as week 4, with substantial reductions observed after 12 weeks of treatment. This faster-acting and sustained efficacy of CAB gel—coupled with its optimized formulation, once-daily dosing, and tolerability—may positively impact treatment adherence. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.7907.
- Published
- 2024
- Full Text
- View/download PDF
191. Natural Moisturizing Factor-Enriched Formulations Compared to a Ceramide-Based Cream.
- Author
-
Baldwin HE, Arrowitz C, and Del Rosso J
- Subjects
- Female, Male, Humans, Ceramides, Emollients, Lower Extremity, Epidermis, Skin
- Abstract
Background: We aimed to investigate the effects of 2 ceramide plus natural moisturizing factor-enriched formulations compared to a ceramide-based cream on skin moisturization., Methods: Two double-blinded comparative studies were conducted, which enrolled 35 (n=29 females, n=6 males) and 33 (n=21 females, n=12 males) participants, respectively. Participants applied ceramide plus natural moisturizer cream or ceramide-based cream (study 1) or applied ceramide plus natural moisturizing factor lotion or ceramide-based cream (study 2) to each of their lower legs for 10 days with a 5-day regression period (no moisturizer applied). Skin hydration by corneometry after bilateral application was conducted once daily for each leg in both groups. Results: An increase in corneometer units vs baseline for the ceramide plus natural moisturizing factor-enriched cream and natural moisturizing factor-enriched lotion were greater than the increase vs baseline for the ceramide-based cream at days 10 and 15; with an overall statistical significance in favor of the ceramide plus natural moisturizing factor-enriched formulations at day 10. Conclusions: The marked improvement in skin moisturization following utilization of the ceramide plus natural moisturizing factor-enriched cream and lotion compared to the ceramide-based cream can be attributed to the inherent properties of the natural moisturizing factors. These properties are known to maintain the humectancy and intercellular lipid membrane of the stratum corneum, which directly improves the permeability barrier function of human skin in reducing transepidermal water loss. J Drugs Dermatol. 2024;23(3): doi:10.36849/JDD.8172.
- Published
- 2024
- Full Text
- View/download PDF
192. Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape.
- Author
-
Desai SR, Baldwin H, Del Rosso JQ, Gallo RL, Bhatia N, Harper JC, York JP, and Gold LS
- Subjects
- Adult, Humans, Benzoyl Peroxide therapeutic use, Metronidazole therapeutic use, Quality of Life, Randomized Controlled Trials as Topic, Dermatologic Agents therapeutic use, Rosacea drug therapy
- Abstract
Rosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients' quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment landscape for rosacea management, as it is not yet included in clinical guidelines that predominantly rely on older approved therapies. The review focuses on randomized controlled trials conducted in English-speaking adults. It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream. Existing therapies have been effective in reducing papulopustular lesions and erythema associated with rosacea for many years. E-BPO 5% offers a promising addition to the treatment options due to its microencapsulation technology, which prolongs drug delivery time and aims to improve therapeutic response while minimizing skin irritation. Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
193. INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study.
- Author
-
Graber E, Baldwin HE, Fried RG, Rieder EA, Hebert AA, Del Rosso J, Kircik L, Stein Gold L, Harper JC, Alexis AF, Narayanan S, Koscielny V, and Kasujee I
- Subjects
- Child, Humans, Activities of Daily Living, Prospective Studies, Treatment Outcome, Social Interaction, Acne Vulgaris diagnosis, Acne Vulgaris drug therapy, Tetracyclines
- Abstract
Background: Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients’ functioning and activities of daily living (ADL) are needed., Methods: A 12-week, single-arm, prospective cohort study was conducted in patients ≥9 years old with moderate/severe non-nodular facial AV prescribed sarecycline as part of usual care. The primary endpoint included AV-specific patient- and caregiver-reported outcomes assessed with the expert panel questionnaire (EPQ, developed by 10 experts using a Delphi method) in patients (>12 years) and caregivers (for patients 9-11 years). Additional assessments included parental/caregiver perspectives on children’s AV., Results: A total of 253 patients completed the study. Following 12-weeks of treatment, there were significant (P ≤.0001) changes from baseline in the proportion of patients responding that they never or rarely: felt angry (31.6%), worried about AV worsening (28.9%), had thoughts about AV (20.9%), had a certain level of worries about AV (38.7%), altered their social media/selfie activity (23.7%), had an impact on real-life plans due to AV (22.9%), made efforts to hide AV (21.3%), felt picked-on/judged due to AV (15.0%), were concerned about their ability to reach future goals due to AV (13.8%), or had sleep impacted due to AV (18.2%). No significant change from baseline was observed for parent/caregiver’s understanding of the child’s AV concerns, from both patient and parent/caregiver perspectives., Conclusions: Over 12 weeks of AV management with oral sarecycline, patients reported significant reductions in AV-related effects on emotional/social functioning and ADL as measured by the EPQ, a simple PRO with potential for use in clinical practice. J Drugs Dermatol. 2024;23:1(Suppl 1):s4-11.
- Published
- 2024
- Full Text
- View/download PDF
194. A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion.
- Author
-
Del Rosso J, Baldwin H, Bhatia N, Chavda R, York JP, Harper J, Hougeir FG, Jackson JM, Noor O, Rodriguez DA, Schlesinger T, and Weiss J
- Abstract
Rosacea is a common, chronic inflammatory disease characterized by both fluctuating and fixed heterogeneous signs such as facial erythema, papules/pustules, telangiectasia, acute vasodilation (flushing), and phymatous changes, and symptoms such as cutaneous stinging and burning. The shift to a phenotype-based approach to rosacea management has improved the consistency of recommendations across recent published guidelines. Consistent and thorough guidance for the classification, diagnosis, and management of the disease is difficult, as the mechanisms underlying the development of rosacea are still not completely understood nor universally accepted. Here, we provide a critical review of current published guidance, and gaps in the knowledge and management of rosacea. We present the recently approved microencapsulated benzoyl peroxide as an effective topical treatment option for papulopustular rosacea. Benzoyl peroxide (BPO) has been used in acne management for many years; however, many clinicians perceive treatment of rosacea with any BPO formulation to be counterintuitive because of concerns of potential skin irritation, while the lack of an accepted mechanism of action on rosacea pathophysiology means that others may be hesitant to use BPO as a treatment. Minocycline foam 1.5% is also an option for the treatment of inflammatory lesions in rosacea, with a decreased risk of systemic adverse events compared with oral minocycline., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
195. INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study.
- Author
-
Baldwin HE, Graber E, Harper JC, Alexis AF, Stein Gold L, Kircik L, Del Rosso J, Hebert AA, Rieder EA, Fried RG, Narayanan S, Koscielny V, and Kasujee I
- Subjects
- Adult, Female, Humans, Child, Male, Prospective Studies, Severity of Illness Index, Treatment Outcome, Immunoglobulin A therapeutic use, Acne Vulgaris diagnosis, Acne Vulgaris drug therapy, Tetracyclines
- Abstract
Background: Patient-reported outcomes (PROs) are emerging as a fundamental component of disease impact assessment in acne vulgaris (AV), complementing clinician-reported outcomes. No data is available on PROs for patients with AV using sarecycline in real-world settings., Methods: A single-arm, prospective cohort study that included patients ≥9 years old diagnosed with moderate or severe non-nodular AV was implemented as part of routine care in clinical practices (N=30). Patients received oral sarecycline (60 mg, 100 mg, or 150 mg) for 12 weeks, as part of usual care. The primary endpoint was Acne Symptom and Impact Scale (ASIS) responses from patients (≥12 years) and caregivers (for patients 9-11 years) at week 12 and change from baseline (CFB). Investigator’s Global Assessment (IGA) of AV severity and adverse events (AEs) were also recorded., Results: A total of 253 patients with AV completed the study (adults: 60.1%, females: 77.6%). ASIS mean scores significantly decreased (P <.0001) at week 12 for: signs (mean CFB ± standard deviation [SD]: –0.8 ± 0.7), impact (–1.0 ± 1.0), emotional impact (–1.2 ± 1.1), and social impact (0.6 ± 1.1). Significant reductions in AV severity (P <.0001) were reported by patients and caregivers. The IGA success rate was 58.9% and physician satisfaction with treatment outcomes was 88.1%. A total of 31 (10.3%) patients reported ≥1 AE during the study., Conclusions: Patients with moderate-to-severe AV receiving acne management with an oral antibiotic for 12 weeks experienced a significant improvement in AV-related symptoms and psychosocial burden. J Drugs Dermatol. 2024;23:1(Suppl 1):s12-18.
- Published
- 2024
- Full Text
- View/download PDF
196. New Insights Into Systemic Drivers of Inflammation and Their Contributions to the Pathophysiology of Acne.
- Author
-
Del Rosso J, Farris PK, Harper J, Baldwin H, Hazan A, and Raymond I
- Subjects
- Adolescent, Humans, Skin microbiology, Sebum metabolism, Inflammation, Acne Vulgaris drug therapy, Microbiota
- Abstract
Acne Vulgaris (AV) is a prominent skin disease commonly affecting teenagers. It often persists into adulthood and is associated with adverse physical and psychosocial impacts. The pathophysiology of AV is conventionally correlated with 4 factors within and around the pilosebaceous unit: increased sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and localized immune responses. As such, conventional therapeutic approaches for AV have primarily focused on these factors. In addition to this primarily localized pathophysiology, there is a progressively emerging body of evidence indicating that underlying systemic factors contributing to a generalized immuno-inflammatory response can contribute to or exacerbate AV. In this article, we introduce and provide the supporting data, for 6 patient-centric systems that may be implicated in the development of AV: psycho-emotional stress, diet and metabolism, dysbiosis of the gut and skin microbiome, hormonal fluctuations, oxidative stress, and immune response. Identifying these pathways and their contributions in a patient-centric approach may provide expanded therapeutic opportunities for treating patients with AV. J Drugs Dermatol. 2024;23(2):90-96. doi:10.36849/JDD.8137.
- Published
- 2024
- Full Text
- View/download PDF
197. Management of Acne Vulgaris With Trifarotene.
- Author
-
Tan J, Chavda R, Baldwin H, and Dreno B
- Subjects
- Humans, Administration, Cutaneous, Retinoids, Dermatologic Agents, Acne Vulgaris drug therapy, Acne Vulgaris chemically induced
- Abstract
Topical retinoids have an essential role in treatment of acne. Trifarotene, a topical retinoid selective for retinoic acid receptor (RAR) γ, is the most recent retinoid approved for treatment of acne. RAR-γ is the most common isoform of RARs in skin, and the strong selectivity of trifarotene for RAR-γ translates to efficacy in low concentration. Trifarotene, like other topical retinoids, acts by increasing keratinocyte differentiation and decreasing proliferation, which reduces hyperkeratinization. Retinoids have also been shown to inhibit inflammatory pathways via effects on leukocyte migration, toll-like receptors, and Activator Protein (AP)-1. Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne. However, unlike all other retinoids, trifarotene is the first topical retinoid with rigorous clinical data on safety and efficacy in truncal acne. Data supporting use of trifarotene to manage acne are reviewed in this publication.
- Published
- 2023
- Full Text
- View/download PDF
198. Role of Retinoic Acid Receptor Subtypes in the Pathophysiology of Acne.
- Author
-
Dréno B, Zouboulis CC, Tan J, Baldwin H, Krishnaswamy JK, and Chavda R
- Subjects
- Humans, Tretinoin, Receptors, Retinoic Acid, Acne Vulgaris diagnosis
- Published
- 2023
- Full Text
- View/download PDF
199. Unmet Needs in the Management of Acne Vulgaris: A Consensus Statement.
- Author
-
Baldwin H, Farberg A, Frey C, Hartman C, Lain E, Meltzer R, and Draelos Z
- Subjects
- Adult, Adolescent, Humans, Propionates, Cortodoxone, Sebum, Treatment Outcome, Acne Vulgaris diagnosis, Acne Vulgaris drug therapy
- Abstract
Acne vulgaris is the most common skin condition in the US, affecting up to 50 million Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment were developed to provide recommendations for the diagnosis, grading, and treatment of acne in adolescents and adults to support clinicians in their therapeutic decision-making process. The most recent acne guidelines were published in 2016, and the approach to care and the therapeutic landscape of acne have evolved since that time. The Acne Management Consensus Roundtable was convened in 2022 to discuss unmet needs in the management of acne. The main focus of the meeting was the role of androgens in acne pathology; the evaluation of clascoterone, the first topical anti-androgen that specifically addresses sebum production in acne; and the identification of the place of clascoterone in therapy. Clascoterone was approved by the US Food and Drug Administration for the treatment of acne in patients 12 years and older in 2020. This report aims to highlight important limitations of the 2016 AAD treatment guidelines and to familiarize practitioners with clascoterone and its indication, efficacy and safety profile, and potential use across diverse patient populations. With its new mechanism of action, clascoterone may be able to fulfill important unmet needs in acne treatment. Baldwin H, Farberg AS, Frey C, et al. Unmet needs in the management of acne vulgaris: a consensus statement. J Drugs Dermatol. 2023;22(6):582-587. doi:10.36849/JDD.7587.
- Published
- 2023
- Full Text
- View/download PDF
200. The Personalized Acne Treatment Tool - Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of Experts.
- Author
-
Layton AM, Alexis A, Baldwin H, Bettoli V, Del Rosso J, Dirschka T, Dréno B, Gold LS, Harper J, Ko JY, Al Nuaimi K, Oon HH, Rajagopalan M, Rocha M, See JA, Weiss J, and Tan J
- Abstract
Background: Acne, a commonly treated skin disease, requires patient-centered management due to its varying presentations, chronicity, and impact on health-related quality of life. Despite this, evidence-based clinical guidelines focus primarily on clinical severity of facial acne, omitting important patient- and disease-related factors, including ongoing management., Objectives: To generate recommendations to support patient-centered acne management, which incorporate priority and prognostic factors beyond conventional clinical severity, traditionally defined by grading the appearance and extent of visible lesions., Methods: The Personalizing Acne: Consensus of Experts consisted of 17 dermatologists who used a modified Delphi approach to reach consensus on statements regarding patient- and treatment-related factors pertaining to patient-centered acne management. Consensus was defined as ≥75% voting "agree" or "strongly agree.", Results: Recommendations based on factors such as acne sequelae, location of acne, high burden of disease, and individual patient features were generated and incorporated into the Personalized Acne Treatment Tool., Limitations: Recommendations are based on expert opinion, which may differ from patients' perspectives. Regional variations in healthcare systems may not be represented., Conclusions: The Personalizing Acne: Consensus of Experts panel provided practical recommendations to facilitate individualized management of acne, based on patient features, which can be implemented to improve treatment outcomes, adherence, and patient satisfaction., Competing Interests: All panel members received honoraria from Galderma for participating in this project. Alison M Layton has acted as an advisor or consultant, been chief investigator for research (funded to institution) and/or received honoraria for unrestricted educational events from Almirall, Beiersdorf, Cipher Pharmaceuticals, Galderma, GlaxoSmithKline, La Roche-Posay, LEO Pharma, L’Oreal, Mylan, Origimm, and Proctor and Gamble. Andrew Alexis has received grant/research support (funds to institution) from Abbvie, Almirall, Amgen, Arcutis, Bausch Health, Bristol-Myers Squibb, Cara, Castle, Dermavant, Galderma, LEO Pharma, Novartis, Vyne, acted as a consultant/advisory board attendee for Abbvie, Allergan, Almirall, Amgen, Arcutis, Bausch Health, Beiersdorf, BMS, Cara, Cutera, Dermavant, Eli Lilly, EPI, Galderma, Janssen, LEO Pharma, L’Oreal, Ortho, Pfizer, Sanofi-Regeneron, Sol-Gel, Swiss American, UCB, VisualDx, Vyne. Hilary Baldwin has acted as an investigator, consultant, and/or speaker for Almirall, Bausch Health, Cassiopea, EPI Health, Galderma, La Roche-Posay, L’Oreal, Mayne Pharma, Sol-Gel, Sun Pharma, and Vyne. Vincenzo Bettoli has acted as a consultant, advisory board member, research investigator and received honoraria from AbbVie, Beiersdorf, Bioderma, Biogena, Difa-Cooper, Galderma, Ganassini, GlaxoSmithKline, ICF, LEO Pharma, L’Oreal, Meda, Menarini-Relife, Mylan, Novartis, Pharcos-Biodue, UCB Pharma, and received research support (funds to institution) from AbbVie. James Del Rosso has acted as a research investigator, consultant and/or speaker for Almirall, Bausch Health (Ortho Dermatology), BiopharmX, EPI Health, Galderma, LEO Pharma, Mayne Pharma, Sol-Gel, Sonoma, Sun Pharma, and Vyne Therapeutics (Foamix). Thomas Dirschka has received grants/research support from Almirall, Biofrontera, Galderma, Meda, Schulze & BöhmGmbH, has lectured for Almirall, Biofrontera, Galderma, GlaxoSmithKline, Infectopharm, Janssen-Cilag, LEO Pharma, Meda, Neracare, Novartis, Riemser and is an advisory board member for Almirall, Biofrontera, Dr Pfleger, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Meda, Neracare, Novartis, and Scibase. Brigitte Dréno has acted as investigator, consultant and/or speaker for Almirall, Avène, Bioderma, Fabre, Galderma, La RochePosay, L’Oreal, Novartis, and Sun Pharma. Linda Stein Gold has acted as an investigator/advisor and/or speaker for Almirall, Foamix, Galderma, Novartis, Ortho Derm, Sol-Gel, and Sun Pharma. Julie Harper has acted as a consultant for Almirall, BioPharmX, Cassiopea, Cutera, EPI, Foamix, Galderma, Ortho Derm, Sol-Gel, and Sun Pharma. Joo Yeon Ko has acted as a primary investigator for research (funded to institution) and/or received honoraria for unrestricted educational events from Amorepacific, Eli Lilly, and Galderma. Khaled Al Nuaimi has no relevant disclosures. Hazel H Oon has acted as a speaker, advisory board member and researcher for Galderma, a clinical investigator for Janssen, Novartis, and Pfizer and an advisory board member and speaker for AbbVie, Eli Lilly, and LEO Pharma. Murlidhar Rajagopalan has acted as a speaker and advisor for Galderma India, a consultant for Galderma and a speaker for Janssen, MSD, Novartis, Pfizer, Roche, and Sanofi. Marco Rocha has acted as an advisor, consultant, investigator and/or speaker and received grants/honoraria from Eucerin, FQMMelora, Galderma, Hypera, Johnson & Johnson, La Roche Posay, LEO Pharma, and Pierre-Fabre. Jo-Ann See has acted as an advisor, consultant, advisory board member and/or speaker for Allergan, Galderma, La Roche-Posay, LEO Pharma, L’Oreal, Mayne Pharma, and Viatris. Jonathan Weiss has acted as an investigator/advisor and/or speaker for Almirall, Dr Reddy’s, EPI Health, Foamix, Galderma, Novartis, and Ortho Derm. Jerry Tan has acted as an advisor, consultant, investigator and/or speaker and received grants/honoraria from Almirall, Bausch Health, Boots/Walgreens, Botanix, CeraVe, Cipher Pharmaceuticals, Cutera, Galderma, La Roche-Posay, Novan, Novartis, Pfizer, Promius, Sun Pharma, and Vichy., (© 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.